Novavax Receives Full Marketing Authorization For Prototype COVID-19 Vaccine Nuvaxovid In United Kingdom
Portfolio Pulse from Benzinga Newsdesk
Novavax, Inc. (NASDAQ:NVAX) has received full marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for its prototype COVID-19 vaccine Nuvaxovid for individuals aged 12 and older. The authorization is based on two Phase 3 trials and a Phase 2a/b trial. The company is also working with the MHRA for the rapid review of its updated protein-based non-mRNA COVID-19 vaccine.
October 18, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax's full marketing authorization for its prototype COVID-19 vaccine in the UK could potentially boost its stock in the short term. The company's ongoing work on an updated version of the vaccine also indicates potential future growth.
The full marketing authorization for Novavax's prototype COVID-19 vaccine in the UK is a significant milestone for the company, which could positively impact its stock. Additionally, the company's work on an updated version of the vaccine suggests potential for future growth, which could further boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100